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Introduction: Eplerenone is publicized to be extremely effective in reducing mortality from heart failure with a reasonable side effect profile. 
However it is much more expensive compared to older aldosterone antagonists. We reviewed available evidence to assess if increased expense was 
justified with outcomes data.
Methods and Results: The authors searched the PubMed, CENTRAL, CINAHL and EMBASE databases for randomized controlled trials from 1990 
through July, 2011. Interventions included aldosterone antagonists (aldactone, canrenone, eplerenone) in systolic heart failure. The comparator 
included standard medical therapy and/or placebo. Outcomes assessed were mortality in the intervention versus the comparator groups, and rates 
of adverse events at the end of at least 8 weeks of follow up. Event rates were compared using a forest plot of relative risk (95% confidence interval 
[CI]) using a random effects model (Mantel-Haenszel) between the aldosterone antagonists and controls. We included 13 studies for aldosterone 
antagonists other than eplerenone, and 3 studies for eplerenone. There was significant reduction of mortality with all aldosterone antagonists, but 
eplerenone (15% mortality relative reduction, RR 0.85, 95% CI 0.77-0.93; p=0.0007) was outperformed by other aldosterone antagonists, namely 
spironolactone and canrenone (26% mortality relative reduction, RR 0.74, 95% CI 0.66-0.83; p<0.0001). Reduction in cardiovascular mortality 
with eplerenone was 17% (RR 0.83, 0.75-0.92; p=0.0005) while that with other aldosterone antagonists was 25% (RR 0.75, 95%CI 0.67-0.84, 
p<0.0001) without contributing significantly to an improved side effect profile.
Conclusion: Eplerenone does not appear to be more effective in reducing clinical events compared to older, less expensive aldosterone 
antagonists.
